ANDEMBRY® is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in HAE patients. The approval marks the fifth regulatory approval of ANDEMBRY, reinforcing CSL ...
Hosted on MSN1mon
Has CSL lost its shine as the market's favourite growth story?CSL shares tumbled 4.95% on the day of its half-year results after revenue, net profits and dividends missed market expectations Behring and Vifor outperformed, while Seqirus underperformed due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback